Vita Life SciencesASX:VLS 94 Interest Coverage is 48.83 as of Dec. 2025, which is 5% above its 10-year median of 46.42. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 685 Drug Manufacturers companies, Vita Life Sciences ranks better than 68.47% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Vita Life Sciences's
Operating Income
for the
six
months ended in Dec. 2025 was A$7.57 Mil. Vita Life Sciences's Interest Expense for the
six
months ended in Dec. 2025 was A$-0.16 Mil.
Vita Life Sciences's interest coverage for the quarter that ended in Dec. 2025 was 48.83.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Vita Life Sciences's Interest Coverage or its related term are showing as below:
ASX:VLS'
s Interest Coverage Range Over the Past 10 Years
Min: 28.13 Med: 46.42 Max: 315.26
Current: 39.84
ASX:VLS's Interest Coverage is ranked better than 68.47% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs ASX:VLS: 39.84
Vita Life Sciences (ASX:VLS) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Vita Life Sciences Interest Coverage Related Terms
Vita Life Sciences Interest Coverage Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a Interest Coverage of 48.83 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vita Life Sciences and its competitors. This is near median its historical median of 46.42. Over the past decade, Vita Life Sciences' Interest Coverage has ranged from 28.13 to 315.26. According to the industry distribution chart, Vita Life Sciences ranks #216 out of 685 companies in the Drug Manufacturers industry, placing it in the top 31.5%.
Is Vita Life Sciences' Interest Coverage too high?
Vita Life Sciences' current Interest Coverage of 48.83 is near median its 10-year median of 46.42. Over the past 10 years, this metric has ranged from a low of 28.13 to a high of 315.26. The Drug Manufacturers industry median Interest Coverage is 12.78. Vita Life Sciences' value of 48.83 is 282.1% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #216 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #216 out of 685 companies for Interest Coverage. This puts Vita Life Sciences in the upper half of its industry. The industry median Interest Coverage is 12.78. Vita Life Sciences' value of 48.83 is 282.1% above this benchmark. Historically, Vita Life Sciences' own Interest Coverage has ranged from 28.13 to 315.26 over the past decade. While the company's 10-year median is 46.42 vs. the industry median of 12.78, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Interest Coverage of 48.83 is 282.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Interest Coverage is 48.83, which is near median its own 10-year median of 46.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current Interest Coverage is 48.83, which is near median its 10-year median of 46.42 and 282.1% above the Drug Manufacturers industry median of 12.78. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Interest Coverage is 48.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Interest Coverage: 48.83 (near median its 10-year median of 46.42)
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
Industry Position: 282.1% above the Drug Manufacturers median (#216 of 685)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score
Get the complete analysis for ASX:VLS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
